Hydrocortisone - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.45 [0.20, 1.02]< 10%1 study (1/-)97.2 %NAnot evaluable crucial-
death or ventilation 0.71 [0.37, 1.35]< 10%1 study (1/-)85.3 %NAnot evaluable important-
hospital discharge 1.67 [0.87, 3.19]> 10%1 study (1/-)93.9 %NAnot evaluable important-
mechanical ventilation 0.95 [0.44, 2.04]< 10%1 study (1/-)55.3 %NAnot evaluable important-

safety endpoints 00

superinfection 0.81 [0.49, 1.34]< 10%1 study (1/-)79.2 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.